Nemzeti Gyógyszerkutatási és Fejlesztési Laboratórium (PharmaLab)(RRF-2.3.1-21-2022-00015)
Támogató: NKFIH
(1209-18 314)
(1257-21 305)
Hyperthermia, the raising of tumor temperature (≥39°C), holds great promise as an
adjuvant treatment for cancer therapy. This review focuses on 2 key aspects of hyperthermia:
its molecular and cellular effects and its impact on the immune system. Hyperthermia
has profound effects on critical biological processes. Increased temperatures inhibit
DNA repair enzymes, making cancer cells more sensitive to chemotherapy and radiation.
Elevated temperatures also induce cell cycle arrest and trigger apoptotic pathways.
Furthermore, hyperthermia modifies the expression of heat shock proteins, which play
vital roles in cancer therapy, including enhancing immune responses. Hyperthermic
treatments also have a significant impact on the body's immune response against tumors,
potentially improving the efficacy of immune checkpoint inhibitors. Mild systemic
hyperthermia (39°C-41°C) mimics fever, activating immune cells and raising metabolic
rates. Intense heat above 50°C can release tumor antigens, enhancing immune reactions.
Using photothermal nanoparticles for targeted heating and drug delivery can also modulate
the immune response. Hyperthermia emerges as a cost-effective and well-tolerated adjuvant
therapy when integrated with immunotherapy. This comprehensive review serves as a
valuable resource for the selection of patient-specific treatments and the guidance
of future experimental studies.